An examination of such an association would inform the roles of the genetic polymorphisms of SLC6A2 in the effectiveness of MPH treatment on core deficits of ADHD and further clarify the roles of the noradrenergic systems in the genetic basis of ADHD. This evidence concerns the gene SLC6A2 and attention deficit-hyperactivity disorder.